Victoza® is indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.1
Victoza® works in the liver, pancreas, and gut to control blood glucose by lowering hepatic glucose output, increasing insulin production, and slowing gastric emptying.1
Structural modifications of both the Victoza® and Ozempic® molecules prevent degradation by DPP-4 and prolong incretin activity.1,2 Victoza® is a GLP-1 analog with 97% similarity to human GLP-1.1 Ozempic® is a GLP-1 analog with 94% similarity to human GLP-1.2
Ozempic® delivers week-long coverage with an elimination half-life of ~7 days.2 See the Ozempic® molecule.
Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.
No dose adjustment of Victoza® is recommended for patients with renal impairment. In the Victoza® arm of the LEADER trial, no overall differences in safety or efficacy were seen in patients with mild, moderate, or severe renal function compared to those with normal renal function.1
There is limited experience with Victoza® in patients with end stage renal disease. There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.1 Use caution when initiating or escalating doses of Victoza® in patients with renal impairment.
In the ELLIPSE trial, 134 patients with type 2 diabetes aged 10 to 17 were randomized to receive liraglutide up to 1.8 mg/day or placebo, in combination with metformin with or without basal insulin over a 26-week, double-blinded period followed by a 26-week, open-label extension period. The primary endpoint was change in A1C from baseline at week 26.3
In LEADER, Victoza® reduced the risk of MACE, in adults with type 2 diabetes and established cardiovascular disease. See LEADER results here.
The CV safety of once-weekly Ozempic® was also evaluated in a 2-year CVOT.2,a,b View the CVOT results for Ozempic® and consider if it’s an option for your appropriate adult patients.
aThe primary composite endpoint was the time from randomization to first occurrence of a MACE: CV death, nonfatal myocardial infarction, or nonfatal stroke.
bResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial.
Ozempic® is a once-weekly GLP-1 RA therapy option. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.2 Learn more about Ozempic®.
About taking Victoza®
Patients should inject Victoza® subcutaneously once-daily at any time of day, independently of meals, in the abdomen, thigh, or upper arm.1
Victoza® comes in a prefilled, multidose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.1
Initiate Victoza® with a dose of 0.6 mg daily for one week for your adult patients with type 2 diabetes. The 0.6-mg dose is a starting dose intended to reduce gastrointestinal symptoms during initial titration and is not effective for glycemic control in adults.
After one week at 0.6 mg per day, increase the dose to 1.2 mg daily. If additional glycemic control is required, increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2-mg daily dose.1
Initiate Victoza® with a dose of 0.6 mg daily. After at least one week at 0.6 mg daily, the dose may be increased to 1.2 mg daily if additional glycemic control is required.
If additional glycemic control is required, increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg-daily dose.1
We’re committed to affordable options for your patients. That is why we’ve created a savings program to help lower the cost for commercially insured patients. Encourage patients to request or activate a savings card at VictozaSavings.com.
Eligible patients pay as little as $25 for their Victoza® prescription.a
aCommercial insurance required. Up to a maximum benefit of $100 per prescription for 24 months. Eligibility and other restrictions apply.
VictozaCare™ is a free, personalized resource offering videos, downloadable books, recipes, interactive trackers, a digital coaching program, and more. This online program is designed to help patients build the skills they need to manage their diabetes. Encourage your patients to sign up today.